QCG
KRTX

Quadrant Capital Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Quadrant Capital Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-103
Closed -$32.6K – 2797
2023
Q4 		$32.6K Buy
103
+50
+94% +$9.72K ﹤0.01% 1594
2023
Q3 		$8.96K Buy
53
+11
+26% +$2.07K ﹤0.01% 2018
2023
Q2 		$9.11K Buy
42
+1
+2% +$214 ﹤0.01% 2031
2023
Q1 		$7.45K Sell
41
-47
-53% -$8.99K ﹤0.01% 2132
2022
Q4 		$17.3K Buy
88
+14
+19% +$3K ﹤0.01% 1719
2022
Q3 		$17K Buy
74
+33
+80% +$6.68K ﹤0.01% 1640
2022
Q2 		$5K Buy
+41
New +$4.71K ﹤0.01% 2001

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Quadrant Capital Group's KRTX Position: Q1 2024 in Review

Quadrant Capital Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 103 shares — an estimated $32.6K sold.

Quadrant Capital Group first reported a position in KRTX in Q2 2022 and held it in 7 quarters. The position peaked at $32.6K in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Quadrant Capital Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 103 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $32.6K.
  • Quadrant Capital Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
  • Quadrant Capital Group's Karuna Therapeutics, Inc. Common Stock position peaked at $32.6K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.